3 hours Poseida Therapeutics (NASDAQ:PSTX) Rating Reiterated by HC WainwrightMarketBeat
HC Wainwright reiterated a “buy” rating and set a $20.00 price objective on shares of Poseida Therapeutics in a report on Thursday.
XHC Wainwright reiterated a “buy” rating and set a $20.00 price objective on shares of Poseida Therapeutics in a report on Thursday.
X